$DHAI
DIH HOLDING US, INC.

2022 Q4 Form 10-K Financial Statement

#000119312523105389 Filed on April 19, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $494.9K -$8.309M
YoY Change -83194.7%
Operating Profit -$1.705M
YoY Change -106.04%
Interest Expense $1.648M $8.051M
YoY Change -2426.89%
% of Operating Profit
Other Income/Expense, Net -$56.42K $5.191M
YoY Change -9207.25%
Pretax Income $1.153M $6.604M
YoY Change -66141.6%
Income Tax
% Of Pretax Income
Net Earnings $1.153M $6.604M
YoY Change -66141.55%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.05 $0.28
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $191.1K $191.1K
YoY Change 173.0%
Cash & Equivalents $191.1K
Short-Term Investments
Other Short-Term Assets $284.6K $284.6K
YoY Change -88.49%
Inventory
Prepaid Expenses $284.6K
Receivables
Other Receivables
Total Short-Term Assets $475.7K $475.7K
YoY Change 627.67% 579.57%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $206.9M $206.9M
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $206.9M $206.9M
YoY Change 67199.47% 68859.97%
TOTAL ASSETS
Total Short-Term Assets $475.7K $475.7K
Total Long-Term Assets $206.9M $206.9M
Total Assets $207.4M $207.4M
YoY Change 55524.87% 55942.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $387.2K $387.2K
YoY Change -92.55%
Accrued Expenses $50.00K $50.00K
YoY Change -54.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $437.2K $437.2K
YoY Change 22.2% 21.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.659M $7.659M
YoY Change -1.6%
Total Long-Term Liabilities $7.659M $7.659M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $437.2K $437.2K
Total Long-Term Liabilities $7.659M $7.659M
Total Liabilities $8.097M $8.097M
YoY Change 2163.27% 2149.05%
SHAREHOLDERS EQUITY
Retained Earnings -$7.621M
YoY Change 76397.17%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.621M $199.3M
YoY Change
Total Liabilities & Shareholders Equity $207.4M $207.4M
YoY Change 55524.87% 55942.05%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $1.153M $6.604M
YoY Change -66141.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$51.51K -$1.096M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$204.0M
YoY Change -66991.8%
Cash From Investing Activities $0.00 -$204.0M
YoY Change 18165.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $202.0M
YoY Change
Debt Paid & Issued, Net $242.8K
YoY Change
Cash From Financing Activities -14.51K 205.2M
YoY Change 293102.41%
NET CHANGE
Cash From Operating Activities -51.51K -1.096M
Cash From Investing Activities 0.000 -204.0M
Cash From Financing Activities -14.51K 205.2M
Net Change In Cash -66.02K 125.7K
YoY Change 79.61%
FREE CASH FLOW
Cash From Operating Activities -$51.51K -$1.096M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001883788
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41250
CY2022 dei Entity Registrant Name
EntityRegistrantName
AURORA TECHNOLOGY ACQUISITION CORP.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1624542
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4 Embarcadero Center
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1449
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94105
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
550-0458
CY2022 dei Security12b Title
Security12bTitle
Class A Ordinary Shares, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
ATAK
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
203184730
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2021Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022Q4 us-gaap Cash
Cash
191103
CY2021Q4 us-gaap Cash
Cash
65373
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
284597
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2022Q4 us-gaap Assets Current
AssetsCurrent
475700
CY2021Q4 us-gaap Assets Current
AssetsCurrent
65373
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
206879903
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
0
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
307402
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
206879903
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
307402
CY2022Q4 us-gaap Assets
Assets
207355603
CY2021Q4 us-gaap Assets
Assets
372775
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
387158
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9947
CY2022Q4 atak Accrued Offering Costs
AccruedOfferingCosts
50000
CY2021Q4 atak Accrued Offering Costs
AccruedOfferingCosts
104990
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
242801
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
437158
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
357738
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
589420
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q4 atak Deferred Underwriting Commissions Noncurrent
DeferredUnderwritingCommissionsNoncurrent
7070000
CY2021Q4 atak Deferred Underwriting Commissions Noncurrent
DeferredUnderwritingCommissionsNoncurrent
0
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7659420
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0
CY2022Q4 us-gaap Liabilities
Liabilities
8096578
CY2021Q4 us-gaap Liabilities
Liabilities
357738
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
206879903
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24425
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7621413
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9963
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7620878
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15037
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207355603
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
372775
CY2022 atak Formation And Operating Costs
FormationAndOperatingCosts
1705315
atak Formation And Operating Costs
FormationAndOperatingCosts
9963
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1705315
us-gaap Operating Income Loss
OperatingIncomeLoss
-9963
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5191127
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
258440
CY2022 atak Dividend Income On Trust Account
DividendIncomeOnTrustAccount
2859903
atak Dividend Income On Trust Account
DividendIncomeOnTrustAccount
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
-8309470
CY2022 us-gaap Net Income Loss
NetIncomeLoss
6604155
us-gaap Net Income Loss
NetIncomeLoss
-9963
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15037
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
CY2022 atak Stock Issued During Period Representative Shares Issued Value
StockIssuedDuringPeriodRepresentativeSharesIssuedValue
3030000
CY2022 atak Rights Underlying The Units Value
RightsUnderlyingTheUnitsValue
15596420
CY2022 us-gaap Net Income Loss
NetIncomeLoss
6604155
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7620878
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Net Income Loss
NetIncomeLoss
-9963
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15037
CY2022 us-gaap Net Income Loss
NetIncomeLoss
6604155
us-gaap Net Income Loss
NetIncomeLoss
-9963
CY2022 atak Investmentincomedividends
Investmentincomedividends
2859903
CY2022 atak Allocation Of Deferred Offering Costs For Warrant Liability
AllocationOfDeferredOfferingCostsForWarrantLiability
516746
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5191127
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
258440
CY2022 atak Payment Of Advertising And Marketing Costs By Sponsor
PaymentOfAdvertisingAndMarketingCostsBySponsor
0
atak Payment Of Advertising And Marketing Costs By Sponsor
PaymentOfAdvertisingAndMarketingCostsBySponsor
17
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
284597
CY2022 atak Increase Decrease In Accounts Payable And Accrued Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpenses
377211
atak Increase Decrease In Accounts Payable And Accrued Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpenses
9947
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1095955
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1
CY2022 atak Dividends Received From Interest Earned On Marketable Securities Held In Trust Account
DividendsReceivedFromInterestEarnedOnMarketableSecuritiesHeldInTrustAccount
-204020000
atak Dividends Received From Interest Earned On Marketable Securities Held In Trust Account
DividendsReceivedFromInterestEarnedOnMarketableSecuritiesHeldInTrustAccount
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-204020000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2022 atak Payment Of Underwriting Fee
PaymentOfUnderwritingFee
2525000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6470000
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
242801
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2022 atak Payment Of Offering Costs
PaymentOfOfferingCosts
460514
atak Payment Of Offering Costs
PaymentOfOfferingCosts
84628
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205241685
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65372
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
125730
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
65373
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65373
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
191103
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65373
CY2022 atak Initial Measurement Of Classa Ordinary Shares Subject To Possible Redemption
InitialMeasurementOfClassaOrdinarySharesSubjectToPossibleRedemption
174013413
CY2022 atak Initial Measurement Of Public Warrants And Private Placement Warrants
InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants
5780547
atak Initial Measurement Of Public Warrants And Private Placement Warrants
InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants
CY2022 atak Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
7070000
CY2022 atak Remeasurement Of Class A Ordinary Shares Subject To Possible Redemption
RemeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption
32866490
atak Remeasurement Of Class A Ordinary Shares Subject To Possible Redemption
RemeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption
CY2022 atak Forfeiture Of Founder Shares
ForfeitureOfFounderShares
-70
CY2022 atak Stock Issued During Period Representative Shares Issued Value Class A
StockIssuedDuringPeriodRepresentativeSharesIssuedValueClassA
30
CY2022 atak Deferred Offering Costs Incurred Included In Accrued Offering Costs
DeferredOfferingCostsIncurredIncludedInAccruedOfferingCosts
50000
atak Deferred Offering Costs Incurred Included In Accrued Offering Costs
DeferredOfferingCostsIncurredIncludedInAccruedOfferingCosts
104990
atak Non Cash Borrowings Against Promissory Note
NonCashBorrowingsAgainstPromissoryNote
92801
us-gaap Stock Issued1
StockIssued1
25000
CY2022Q1 atak Overallotment Option Liability
OverallotmentOptionLiability
258440
CY2022Q1 atak Stock Issued During Period Representative Shares Issued Value
StockIssuedDuringPeriodRepresentativeSharesIssuedValue
3030000
CY2022Q1 atak Rights Underlying The Units Value
RightsUnderlyingTheUnitsValue
15596420
CY2022Q4 atak Percentage Of Fair Market Value Of Target Business To Asset Held In Trust Account
PercentageOfFairMarketValueOfTargetBusinessToAssetHeldInTrustAccount
80
CY2022Q4 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001
CY2022 atak Business Combination Extension Of Business Combination Period
BusinessCombinationExtensionOfBusinessCombinationPeriod
Combination Period six (6) times for an additional one (1) month each time
CY2022 atak Number Of Days Within Which Public Shares Shall Be Redeemed
NumberOfDaysWithinWhichPublicSharesShallBeRedeemed
P10D
CY2022Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
50000
CY2022Q4 atak Operating Cash
OperatingCash
191103
CY2022Q4 atak Net Working Capital Surplus Deficit
NetWorkingCapitalSurplusDeficit
38542
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.</div>
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 atak Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated
PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated
1
CY2022Q1 atak Stock Issued During Period Representative Shares Issued Value
StockIssuedDuringPeriodRepresentativeSharesIssuedValue
3030000
CY2022Q1 atak Rights Underlying The Units Value
RightsUnderlyingTheUnitsValue
15596420
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26670000
CY2022 atak Minimum Lock In Period For Transfer Assign Or Sell Warrants After Completion Of Ipo
MinimumLockInPeriodForTransferAssignOrSellWarrantsAfterCompletionOfIpo
P30D
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
589420
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0

Files In Submission

Name View Source Status
0001193125-23-105389-index-headers.html Edgar Link pending
0001193125-23-105389-index.html Edgar Link pending
0001193125-23-105389.txt Edgar Link pending
0001193125-23-105389-xbrl.zip Edgar Link pending
atak-20221231.xsd Edgar Link pending
atak-20221231_cal.xml Edgar Link unprocessable
atak-20221231_pre.xml Edgar Link unprocessable
atak-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d401758d10k.htm Edgar Link pending
d401758dex311.htm Edgar Link pending
d401758dex312.htm Edgar Link pending
d401758dex321.htm Edgar Link pending
d401758dex322.htm Edgar Link pending
d401758dex41.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
d401758d10k_htm.xml Edgar Link completed
atak-20221231_lab.xml Edgar Link unprocessable